Fundraising Fox

Cornerstone Pharmaceuticals

Cranbury,, US · 19 employees on LinkedIn

Cornerstone Pharmaceuticals develops anti-metabolic cancer therapies and is testing its lead drug candidate, CPI-613 (devimistat), in combinations using preclinical cancer models.

Founders & leadership

RS
Robert ShorrFounder
DA
David A. PolinskyinExecutive
RR
Robert RodriguezExecutive
CH
Clifford H StraubExecutive

Board

PS
Patrick S. WilmerdingBoard director
HJ
Howard JonasBoard director
JA
Joseph A. SternBoard director
AD
Aaron DrillickBoard director
SF
Sim FassBoard director
HG
Herman Gilbert PolinskyBoard director

Reported raises · per SEC filings

Form D private placements

$3.3M disclosed across 1 round · 2014

$3.3MraisedMar 2014 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Patrick S. WilmerdingDirector
  • Howard JonasDirector
  • Joseph A. SternDirector
  • Robert ShorrExecutive Officer, Director
  • Aaron DrillickDirector
  • Sim FassDirector
  • David A. PolinskyExecutive Officer, Director
  • Herman Gilbert PolinskyDirector
  • Robert RodriguezExecutive Officer, Director
  • Clifford H StraubExecutive Officer
Offering amount
$7.5M
Amount sold
$3.3M
Proceeds to insiders
$1.9M
First sale
Feb 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Cornerstone Pharmaceuticals do?
Cornerstone Pharmaceuticals develops anti-metabolic cancer therapies and is testing its lead drug candidate, CPI-613 (devimistat), in combinations using preclinical cancer models.
Who founded Cornerstone Pharmaceuticals?
Cornerstone Pharmaceuticals was founded by Robert Shorr.
How much funding has Cornerstone Pharmaceuticals raised?
Cornerstone Pharmaceuticals has disclosed $3.3M raised across 1 round.
Where is Cornerstone Pharmaceuticals headquartered?
Cornerstone Pharmaceuticals is headquartered in Cranbury,, US.